Gilead Sciences and your company Kite Oncology have announced that they will present more than 20 abstracts at the annual meeting of the American Society of Clinical Oncology (ASCO) of 2022.
As reported by the company in a statement, these data highlight “promising targets” in various types of tumors and blood cancers, including metastatic breast cancer that is hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-), triple negative metastatic breast cancer (TNBC), myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and mantle cell lymphoma (MCL).
“Gilead has built a diverse oncology portfolio guided by our strategic framework, with a depth and breadth approach to address the largest gaps in care for people with neglected and difficult-to-treat cancers.” Merdad Parsey, chief medical officer of Gilead Scienceswhile noting that these data reinforce the potential of their transformative science across multiple types of cancer.
“Gilead has built a diverse oncology portfolio guided by our strategic framework, with a depth and breadth approach to address the largest gaps in care for people with neglected and difficult-to-treat cancers.”
DRIVING SCIENTIFIC INNOVATION IN BREAST CANCER WITH A “GREAT UNMET NEED”
A last minute presentation on the study TROPiCS-02 will examine the investigational use of Gilead’s antibody-drug conjugate in patients with metastatic breast cancer or locally advanced unresectable. Currently, these patients have significantly limited treatment options.
Final data from the historic study will also be presented. ‘ASCENT’ in second line triple negative metastatic breast cancer (TNBC).
ADVANCING A CAR T-CELL THERAPY PORTFOLIO
New analyzes from the phase 3 trial ZUMA-7 will highlight results in patients older than 65 years, as well as data on pre-treatment tumor burden characteristics and clinical outcomes for the first and only approved CAR T-cell therapy for initial treatment of relapsed/LBCL patients refractory.
At Kite, our singular focus is the development of cell therapies to treat and potentially cure cancer. Frank Neumann, Global Director of Clinical Development for Kite. “Our data at ASCO spans multiple blood cancer types and treatment stages, reinforcing how our therapies are changing the way cancer is treated,” added Neumann.
PROMOTION OF POTENTIAL TREATMENT APPROACHES IN MYELODISPLASTIC SYNDROME (MDS) AND ACUTE MYELOID LEUKEMIA (AML)
Similarly, the results of the phase 1b study that evaluates a anti-CD47 antibody investigational in combination with azacitidine in high-risk MDS and TP53-mutated AML.
MDS and AML sound blood cancers that have seen limited therapeutic advances in the past decadeand Gilead data to be presented at ASCO will reinforce the potential to harness innate immunity from macrophages.
Because health we all need… ConSalud.es
–
